We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · August 25, 2021

Docetaxel and Prednisone ± Enzalutamide as First-Line Treatment in Metastatic Castration-Resistant Prostate Cancer

European Journal of Cancer


Additional Info

European Journal of Cancer
Docetaxel and Prednisone With or Without Enzalutamide as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: CHEIRON, a Randomised Phase II Trial
Eur. J. Cancer 2021 Aug 03;[EPub Ahead of Print], O Caffo, C Ortega, F Nolè, et al

Further Reading